Several trial results for the treatment of COPD were shared at the 2023 International Conference. Gerard J. Criner, MD, and David M. Mannino III, MD, discussed findings from the BOREAS trial, expectations from the ongoing NOTUS trial, and data from the ENHANCE-1 and ENHANCE-2 studies.
Timothy R. Aksamit, MD, FCCP, and Mark Metersky, MD, FCCP, comment on updates from multiple studies making headway in treating bronchiectasis. These trials, presented at the ATS 2023 International Conference, reflect research focusing on the three pillars of the disease: infection, inflammation, and mucociliary milieu. The trials included phase three of PROMIS II and phase…
Four highly anticipated trials were presented at the ATS 2023 International Conference. The trials included the TORREY Study of Seralutinib, the ENHANCE Trials of Nebulized Ensifentrine, the Phase 1b Study of SAR443765 in Mild-to-Moderate Asthma, and the BOREAS Study of Dupilumab in COPD Patients with Type 2 Inflammation. Robert P. Frantz, MD, summarized the findings…